Invega is an oral extended-release (ER) major active metabolite of risperidone. It is an antagonist and thus interferes with neurotransmitter communication in the brain. It blocks dopamine type 2, serotonin type 2, and alpha 2 adrenergic receptors, all of which have been implicated in schizophrenia.
Invega is specifically indicated for the treatment of schizophrenia.
Invega is supplied as an extended release tablet available in 3 mg, 6 mg and 9 mg strengths, designed for oral administration. The recommended initial dose of the drug is 6 mg once daily, administered in the morning. The drug was observed to have dose-dependent efficacy, however this related to dose-dependent increases in adverse events. Dose increases above 6 mg/day should be made only after clinical reassessment. The maximum recommended dose is 12 mg/day.
FDA approval of Invega was based on the results of three clinical trials. These placebo-controlled, active-controlled (olanzapine), fixed-dose trials enrolled 1,665 non-elderly adult subjects who met DSM-IV criteria for schizophrenia, internationally. Subjects received placebo or Invega at 3, 6, 9, 12, and 15 mg/day for six weeks. Efficacy was evaluated using the Positive and Negative Syndrome Scale (PANSS) and the Personal and Social Performance (PSP) scale. Results revealed all doses of Invega to be superior to placebo on both the PANSS and PSP scales. The mean effects at all doses were fairly similar, although the higher doses in all studies were numerically superior.
Ongoing Study Commitments
Adverse events associated with the use of Invega may include, but are not limited to, the following:
In addition, Invega was shown to induce orthostatic hypotension and syncope in some patients because of its alpha-blocking activity. Thus, it should be used with caution in patients with known cardiovascular disease, cerebrovascular disease, or conditions that predispose the patient to hypotension.
Invega uses osmotic pressure to deliver paliperidone at a controlled rate. It is an oral extended-release (ER) major active metabolite of risperidone. Although the exact mechanism of action is unknown, it is thought that Invega acts as an antagonist and thus interferes with neurotransmitter communication in the brain. It blocks dopamine type 2, serotonin type 2, and alpha 2 adrenergic receptors, all of which have been implicated in schizophrenia.
For additional information regarding Invega or schizophrenia, please visit the Invega web page.
The Invega drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.